Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 154 recruiting now early-phase tilt #14 of 28,963 conditions

Colorectal Cancer: early-phase trial registry

154 of 382 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,963 conditions by registered trial count.

382 US clinical trials · 154 currently recruiting · #14 of 28,963 conditions by registered trial count

Colorectal Cancer: 382 US clinical trials tracked, 154 recruiting.

Colorectal Cancer is the subject of 382 registered US clinical trials on ClinicalTrials.gov, 154 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Open enrollment, early-phase tilt

Colorectal Cancer has 382 registered US clinical trials, 154 of them open to new participants right now, about 40% of the total.

154
recruiting participants now
40%
of trials open to enrollment
12
in Phase 3-4 (later-stage)
22
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #14 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    154 of 382 indexed trials (40.3%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 382 trials (5.8%). 217 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 370 trials that report a genuine target (sentinel values excluded). 157 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    315 interventional and 67 observational studies make up this index (82.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1128Phase 268Phase 39Phase 43

Open and recent trials

382 total, page 7 of 8

COMPLETED NA 57 participants

Colonoscope Insertion Trial Protocol

UConn Health

NCT01324882

COMPLETED Phase 2 54 participants

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

NCT00381862

COMPLETED Phase 1 54 participants

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT04580485

COMPLETED Phase 2 53 participants

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

University of Colorado, Denver

NCT03475004

COMPLETED NA 51 participants

Preoperative 3D Models and Shared Decision-making

Vanderbilt University Medical Center

NCT06625008

COMPLETED Phase 1 51 participants

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Akamis Bio

NCT02636036

COMPLETED NA 50 participants

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

SWOG Cancer Research Network

NCT01453452

COMPLETED Phase 1 50 participants

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

David Bajor, MD

NCT02861300

COMPLETED Phase 1 49 participants

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

Medical University of South Carolina

NCT00003344

COMPLETED Phase 1 48 participants

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

NCT01451632

COMPLETED Phase 1 48 participants

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences

NCT03629756

COMPLETED Phase 1 48 participants

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Celldex Therapeutics

NCT00709462

COMPLETED 47 participants

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

UNC Lineberger Comprehensive Cancer Center

NCT00280761

COMPLETED Phase 1 47 participants

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

University of Utah

NCT01047293

COMPLETED Phase 1 45 participants

Study of KCC Peptide Application in the Colon

Danielle Kim Turgeon

NCT02156557

COMPLETED Phase 2 45 participants

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

NYU Langone Health

NCT00005049

COMPLETED Phase 2 44 participants

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Academic Thoracic Oncology Medical Investigators Consortium

NCT03542877

COMPLETED Phase 1 44 participants

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT04666688

COMPLETED NA 43 participants

Colonoscopy Screening: Setting Epic Follow-up Times

Massachusetts General Hospital

NCT05631873

COMPLETED Phase 1 42 participants

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Genentech

NCT00671372

COMPLETED Phase 1 42 participants

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Syndax Pharmaceuticals

NCT05731947

COMPLETED NA 42 participants

e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates

Icahn School of Medicine at Mount Sinai

NCT04987788

COMPLETED Phase 2 40 participants

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

St. Vincent Medical Center - Los Angeles

NCT00002475

COMPLETED Phase 1 40 participants

Curcumin Biomarkers

University of North Carolina, Chapel Hill

NCT01333917

COMPLETED NA 40 participants

Energy Balance Interventions for Colorectal Cancer Prevention

Vanderbilt University

NCT00653484

COMPLETED Phase 1 39 participants

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Bristol-Myers Squibb

NCT00441337

COMPLETED Phase 2 38 participants

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Rutgers, The State University of New Jersey

NCT01006369

COMPLETED Phase 1 38 participants

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT03829436

COMPLETED Phase 2 36 participants

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

NYU Langone Health

NCT00444678

COMPLETED Phase 2 35 participants

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Memorial Sloan Kettering Cancer Center

NCT03693807

COMPLETED Phase 2 34 participants

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

M.D. Anderson Cancer Center

NCT01730586

COMPLETED Phase 2 32 participants

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

AstraZeneca

NCT01116271

COMPLETED NA 32 participants

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

M.D. Anderson Cancer Center

NCT02613728

COMPLETED Phase 1 32 participants

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

MediGene

NCT00149396

COMPLETED Phase 2 30 participants

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

OncoNano Medicine

NCT03735680

COMPLETED NA 30 participants

Engaging Black Men in Colorectal Cancer Screening

Virginia Commonwealth University

NCT05980182

COMPLETED Phase 1 29 participants

A Study of a Personalized Neoantigen Cancer Vaccine

Gritstone bio

NCT03639714

COMPLETED NA 29 participants

Pain Coping Skills for Colorectal Cancer Survivors

Duke University

NCT02706301

COMPLETED 25 participants

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Vanderbilt-Ingram Cancer Center

NCT00897793

COMPLETED Phase 2 24 participants

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

University of Louisville

NCT01874860

COMPLETED Phase 1 24 participants

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Mayo Clinic

NCT01950403

COMPLETED Phase 1 24 participants

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00003360

COMPLETED Phase 2 23 participants

Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer

Fox Chase Cancer Center

NCT00021398

COMPLETED NA 23 participants

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT00574353

COMPLETED Phase 2 22 participants

Phase II Trial of RAD001 in Refractory Colorectal Cancer

Swedish Medical Center

NCT00337545

COMPLETED Phase 1 22 participants

Lapatinib and Cetuximab in Patients With Solid Tumors

Georgetown University

NCT01184482

COMPLETED Phase 2 21 participants

Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Case Comprehensive Cancer Center

NCT00002933

COMPLETED Phase 1 18 participants

Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00003543

COMPLETED Phase 1 18 participants

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Poniard Pharmaceuticals

NCT00465725

COMPLETED Phase 1 18 participants

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04803305

← Previous Page 7 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 128
Phase 2 68
Phase 3 9
Phase 4 3

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Colorectal Cancer right now

154 recruiting of 382 indexed (40% open).

Phase mix: 12 late (III/IV) vs 196 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (22 trials), 9 others listed. 50 shown below, recruiting first. #14 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Colorectal Cancer?

PlainTrial tracks 382 US clinical trials for Colorectal Cancer, of which 154 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Colorectal Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.